To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. If you experience any issues with your products or services, please contact ATCC Customer Service at sales@atcc.org. For Technical questions please contact tech@atcc.org. Thank you.
X

Privacy Policy Update

We remain dedicated to protecting your data and experience throughout our platforms. We have updated our Privacy Policy and your continued use of the Site means you have accepted the revised Privacy Policy. View now >
X

FAQ's

FAQ Home

Find Answers

Applications of the IDH1 mutant U-87 Isogenic Cell Line

What are the main applications of the IDH1 mutant-U-87 Isogenic Cell Line (ATCC® HTB-14IG ™)?

Together with the parental U-87 MG (ATCC® HTB-14) cells, ATCC® HTB-14IG ™ provides an ideal model for studying tumor-associated IDH1 mutation and its impact during cellular metabolism and epigenetic regulation. In addition this parental and isogenic pair serve as an ideal screening tool for IDH1-specific inhibitors as well as anti-cancer drug discovery and development.

IDH1 and IDH2 mutations are seen in glioma and acute myeloid leukemia as well as in many human cancers. These are cancer driver genes that cause a gain-of-function in tumor cells.  IDH is a metabolic enzyme that interconverts isocitrate and alpha-ketoglutatrate in the TCA cycle.  Cancer-associated point mutations seen in IDH1 and IDH2 confer neomorphic activity resulting in the reduction alpha-KG to the oncometabolite 2-hydroxyglutarate or 2-HG.  High concentrations of 2HG have been shown to inhibit alphaKG-dependent dioxygenases, including histone and DNA demethylases, which alter epigenetic regulation, leading to cellular differentiation and tumorigenesis.

Date Created10/03/2017 11:58 AM
Date Updated10/03/2017 11:58 AM

Most Popular Answers

  1. Huh7 cell line
  2. ATCC HUVEC lines
  3. Passage number vs. population doubling level (PDL)
  4. Converting TCID[50] to plaque forming units (PFU)
  5. U-373 MG (ATCC® HTB-17)